| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5688210 | Kidney International Reports | 2017 | 11 Pages |
Abstract
Our data suggested that the combination of a RAS blocker and a Ã-blocker could improve survival in hemodialysis patients. Further prospective randomized controlled trials are necessary to confirm the beneficial effects of this combination of antihypertensive drugs in patients undergoing hemodialysis.
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
José Luño, Javier Varas, Rosa Ramos, Ignacio Merello, Pedro Aljama, Alejandro MartinMalo, Julio Pascual, Manuel Praga,